Crossmark

Critical evaluation of faecal microbiome preservation using metagenomic analysis

Crossref DOI link: https://doi.org/10.1038/s43705-021-00014-2

Published Online: 2021-05-05

Published Print: 2021-12-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pribyl, Alena L http://orcid.org/0000-0002-7625-5259
Parks, Donovan H

Angel, Nicola Z

Boyd, Joel A

Hasson, Alexander G http://orcid.org/0000-0003-0815-9203
Fang, Liang

MacDonald, Samantha L

Wills, Blake A

Wood, David L A

Krause, Lutz

Tyson, Gene W http://orcid.org/0000-0001-8559-9427
Hugenholtz, Philip http://orcid.org/0000-0001-5386-7925
Funding

Funding for this research was provided by:

Microba Life Sciences

Microba Life Sciences
License Information

Version of Record valid from 2024-01-15

Text and Data Mining valid from 2021-05-05

Version of Record valid from 2021-05-05
More Information

Article History

Received: 23 November 2020

Revised: 14 March 2021

Accepted: 6 April 2021

First Online: 5 May 2021

Competing interests

: This project was funded by Microba Life Sciences. Alena L. Pribyl, Donovan H. Parks, Nicola Angel, Joel Boyd, Lutz Krause, David L.A. Wood, Alexander Hasson, Liang Fang, Samantha L. MacDonald and Blake Wills are employees of Microba Life Sciences. G.W.T. and P.H. are the founders of Microba Life Sciences. Microba Life Sciences is a microbial genomics company developing microbiome-based diagnostics and therapeutics and offers metagenomic gut microbiome reports.

: The parent study (Microba Future Insight Programme—Understanding the Human Microbiome) was approved by the Bellberry Human Research Ethics Committee (HREC Number: 2018-05-400). All participants provided informed consent.